Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:20:09 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



T:ATE - ANTIBE THERAPEUTICS INC. J - http://www.antibethera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATE - T  11.50.105H0.10511.50.295    1.23  0.15Apr 08Apr 2415 min RT 2¢
TSX - T11.50.105H0.10511.50.295    1.23  0.15Apr 0815 min

Recent Trades - All 0 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-24 20:19C:ATE0.295Shares Delisted from TSXAntibe Therapeutics to be delisted from TSX May 24
2024-04-24 13:43C:ATE0.295News ReleaseAntibe's CCAA proceedings ended, receiver appointed
2024-04-19 11:23C:ATE0.295News ReleaseAntibe Therapeutics obtains CCAA stay extension
2024-04-16 17:10C:ATE0.295News ReleaseAntibe Therapeutics under review for listing on TSX
2024-04-09 19:06C:ATE0.295News ReleaseAntibe Therapeutics granted initial order under CCAA
2024-04-09 16:24C:ATE0.295MiscellaneousAntibe Therapeutics under TSX delisting review
2024-04-09 09:35C:ATE0.295News ReleaseAntibe to file for initial order under CCAA
2024-04-09 09:17C:ATE0.295Halt TradingAntibe Therapeutics halted at the open
2024-04-01 09:42C:ATE0.45News ReleaseAntibe's otenaproxesul placed on clinical hold by FDA
2024-03-04 09:29C:ATE0.97News ReleaseAntibe ordered to refund Nuance's $20M (U.S.) payment
2024-02-14 11:31C:ATE0.89News ReleaseAntibe spends $2.3-million on R&D in Q3 2024
2024-02-14 06:35C:ATE0.89SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-14 06:24C:ATE0.89SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-01 10:22C:ATE1.01News ReleaseAntibe extends early warrant exercise incentive program
2023-12-29 09:41C:ATE0.94News ReleaseAntibe arranges early warrant exercise program
2023-12-12 10:43C:ATE0.70News ReleaseAntibe Therapeutics extends warrants to 2024
2023-11-13 11:37C:ATE0.93News ReleaseAntibe spends $3.5M on R&D in fiscal Q2 2024
2023-11-13 06:36C:ATE0.93SEDAR Interim MD & ASEDAR Interim MD & A
2023-11-13 06:34C:ATE0.93SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 10:21C:ATE1.18News ReleaseAntibe talks PK results of otenaproxesul study